Summary: Cigna Healthcare modified its coverage policy for peripheral nerve destruction for pain conditions (Policy 0525), effective April 21, 2026. Here's what billing teams need to know before that date.
Cigna Healthcare — the full official name is Cigna Healthcare — updated its coverage position criteria under Policy 0525 governing peripheral nerve destruction procedures used to treat chronic pain. This policy covers a range of nerve ablation and destruction techniques, and the modification may shift what Cigna considers medically necessary versus experimental. The policy document does not list specific CPT or HCPCS codes in the data available at publication. Until Cigna publishes a complete code list, your billing team should audit all peripheral nerve destruction claims billed to Cigna and confirm coverage status before April 21, 2026.
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Peripheral Nerve Destruction for Pain Conditions |
| Policy Code | 0525 |
| Change Type | Modified |
| Effective Date | April 21, 2026 |
| Impact Level | High |
| Specialties Affected | Pain management, interventional radiology, anesthesiology, neurosurgery, orthopedic surgery, physiatry |
| Key Action | Audit all active Cigna peripheral nerve destruction claims and prior authorization workflows before April 21, 2026 |
Cigna Peripheral Nerve Destruction Coverage Criteria and Medical Necessity Requirements 2026
Cigna's coverage policy for peripheral nerve destruction under Policy 0525 follows a pattern you've seen before — conservative medical necessity criteria with a clear preference for documented conservative care failure before approving more aggressive interventional approaches.
The real issue here is that peripheral nerve destruction sits in a gray zone. It's more invasive than nerve blocks but less invasive than surgical decompression. Cigna, like most commercial payers, draws coverage lines based on the specific nerve target, the destruction method, and the underlying diagnosis driving the pain.
The Cigna Healthcare coverage policy for peripheral nerve destruction generally requires that the treating physician document a diagnosis tied to a specific, identifiable nerve or nerve distribution. Generic "chronic pain" without anatomical specificity is a fast path to claim denial. Your documentation needs to name the nerve — trigeminal, intercostal, suprascapular, medial branch, or whatever the target is — and connect it directly to the patient's pain syndrome.
Medical necessity under this coverage policy typically requires evidence that conservative treatments have failed. That means documented trials of physical therapy, oral analgesics, and often at least one diagnostic nerve block confirming the targeted nerve is the pain generator. If that diagnostic block documentation isn't in the record before you bill the destruction procedure, Cigna will come back for it on appeal — or deny on the front end.
Prior authorization is almost certainly required for peripheral nerve destruction under this policy. Cigna routinely requires prior auth for nerve ablation procedures, particularly radiofrequency ablation and chemical neurolysis. Check your specific plan type before assuming you can bill without it. A missing prior authorization on a high-cost interventional procedure is an expensive administrative mistake.
If your practice bills Cigna for lumbar medial branch radiofrequency neurotomy — one of the highest-volume procedures in this category — you should review prior authorization requirements immediately. These procedures draw intense scrutiny from commercial payers, and Policy 0525 modifications often tighten the criteria around them.
Cigna Peripheral Nerve Destruction Exclusions and Non-Covered Indications
Cigna's historical position under Policy 0525 has classified several peripheral nerve destruction approaches as experimental or investigational. That classification matters because it affects reimbursement directly — experimental procedures don't get paid, and prior authorization won't be granted for them regardless of clinical rationale.
Techniques that have historically drawn experimental or not-covered designations from Cigna in this category include cryoablation of peripheral nerves for non-trigeminal indications, pulsed radiofrequency (as distinct from continuous radiofrequency), and certain chemical neurolysis applications outside tightly defined cancer pain indications. The modification to Policy 0525 may shift some of these designations — but until you see the full updated policy text, treat them as likely still excluded.
The distinction between covered continuous radiofrequency ablation and non-covered pulsed radiofrequency is one Cigna has enforced strictly. If your billing team codes these procedures without understanding which modality was used, you're setting up a claim denial that's hard to appeal after the fact. Get that information from the operative note before claim submission.
Peripheral nerve stimulation implantation — a separate but related procedure — is governed by a different Cigna policy. Don't let a change to Policy 0525 create confusion about stimulation implant coverage. They're different procedures with different coverage tracks.
Coverage Indications at a Glance
Because the policy data available at publication does not include a granular, indication-level breakdown from the updated Policy 0525 document, the table below reflects the general coverage framework for Cigna peripheral nerve destruction procedures based on established policy patterns. Verify each indication against the full April 21, 2026 policy text before billing.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Lumbar medial branch neurotomy (RFA) with positive diagnostic blocks | Covered (when criteria met) | Not specified in current data | Typically requires two confirmatory blocks; prior auth required |
| Cervical medial branch neurotomy (RFA) with positive diagnostic blocks | Covered (when criteria met) | Not specified in current data | Same criteria as lumbar; document block results carefully |
| Trigeminal neuralgia nerve destruction | Covered (when criteria met) | Not specified in current data | Diagnosis specificity critical; surgery-failed or surgery-ineligible patients |
| Intercostal nerve destruction for post-surgical or post-herpetic pain | Covered (select indications) | Not specified in current data | Cancer pain and post-herpetic neuralgia strongest indications |
| Pulsed radiofrequency (PRF) of peripheral nerves | Likely Not Covered / Experimental | Not specified in current data | Cigna historically classifies PRF as investigational |
| Cryoablation of peripheral nerves (non-trigeminal) | Likely Experimental | Not specified in current data | Verify against updated policy text before billing |
| Chemical neurolysis for non-cancer chronic pain | Likely Not Covered | Not specified in current data | Cancer-related pain indications stronger; verify plan-level |
This table reflects general policy patterns. The specific updated criteria from Policy 0525 effective April 21, 2026 should govern your actual billing decisions.
Cigna Peripheral Nerve Destruction Billing Guidelines and Action Items 2026
Here's what to do before April 21, 2026.
| # | Action Item |
|---|---|
| 1 | Pull every open Cigna peripheral nerve destruction case now. Look at scheduled procedures through June 2026. Any case where the service date falls after April 21, 2026 needs to be reviewed against the updated Policy 0525. Don't wait until the day before. |
| 2 | Confirm prior authorization status on all pending cases. If you have authorizations already approved under the old policy criteria, verify with Cigna whether those authorizations remain valid under the modified policy. Some payers honor pre-change authorizations; some don't. Get this in writing from Cigna. |
| 3 | Audit your documentation templates for medical necessity criteria. Make sure your intake process captures diagnostic block results, conservative care failure documentation, and specific nerve targets before the destruction procedure is scheduled. Thin documentation is the number one reason peripheral nerve destruction billing fails at Cigna. |
| 4 | Identify which procedure modalities your physicians use. If any of your providers perform pulsed radiofrequency, cryoablation, or other techniques that Cigna has historically classified as experimental, flag those cases for individual review before April 21, 2026. Don't assume the modification expanded coverage — it may have tightened it. |
| 5 | Request the full updated Policy 0525 document from Cigna. The source document is available at Cigna's coverage policy repository. Your billing guidelines should be based on the actual updated text, not the previous version. If you can't access it directly, your Cigna provider relations representative can send it. |
| 6 | Update your remittance analysis process. After April 21, 2026, watch your Cigna EOBs for new denial codes or reason codes on peripheral nerve destruction claims. A spike in denials in the first 60 days after a policy modification is the clearest signal that your criteria or documentation don't align with the updated coverage policy. |
| 7 | Talk to your compliance officer if your practice has high Cigna volume for these procedures. The financial exposure from a coverage policy modification that tightens medical necessity criteria can be significant, especially in high-volume pain management or interventional radiology practices. If peripheral nerve destruction is a substantial revenue line for your practice, this is a conversation to have before April 21, 2026, not after. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Peripheral Nerve Destruction Under Policy 0525
Code Data Availability
The policy data provided for this modification does not include a specific list of CPT, HCPCS, or ICD-10 codes. Cigna's Policy 0525 document — available at the Cigna coverage policy repository — should contain the full code list associated with this coverage position.
Do not rely on assumed or historically associated codes without confirming them against the April 21, 2026 policy text. Peripheral nerve destruction procedures span a range of CPT codes across thermal ablation, chemical neurolysis, cryoablation, and surgical neurectomy, and the covered versus non-covered code lists can differ significantly from what you expect.
When the full Policy 0525 code list is available, codes in this category typically fall across the following procedure families — but again, confirm the actual codes against the updated document before updating your charge capture:
- Radiofrequency ablation of nerve (various anatomical sites)
- Chemical neurolysis procedures
- Cryoablation of peripheral nerves
- Surgical nerve destruction and neurectomy
Your billing team should compare the code list from the previous version of Policy 0525 against the April 21, 2026 update line by line. If any codes moved from covered to experimental, or if new codes were added to the not-covered list, those are your immediate action items.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.